The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma

Author(s):
Schaeffers, A.W.M.A.; Burger, A.V.M.; Duinkerken, C.W.; Sluis, K.E. van; Boer, J.P. de; Molen, L. van der; Hoetink, A.E.; Al-Mamgani, A.; Józwiak, K.; Devriese, L.A.; Bree, R. de; Zuur, C.L.
Published
2024
Publication type
Article / Letter to editor

Abstract

Introduction: Patients with head and neck squamous cell carcinoma(HNSCC) treated with cisplatin-based chemoradiotherapy (CRT) frequentlyexperience irreversible sensorineural hearing loss (SNHL). Patients with lowlumbar skeletal muscle index (LSMI) may experience higher serum peak dos-ages of cisplatin. This study investigated whether pre-treatment low LSMI isassociated with increased SNHL upon cisplatin-based CRT.Materials and methods: LSMI was assessed using routine pre-treatment CTscans. Pure tone audiometry was performed at baseline and at follow-up toassess treatment-related SNHL. Linear mixed models were used to reveal apotential association between the continuous variable LSMI and SNHL.Results: This retrospective cohort study included 81 patients and found a significantassociation between low LSMI and increased treatment-related SNHL at pure tone fre-quencies vital for the perception of speech (averaged of 1, 2, and 4 kHz) (p = 0.048).Conclusions: HNSCC patients with low LSMI suffer increased treatment-related SNHL upon cisplatin-based CRT.

Date issued
2024
Language
English
Is part of
Head and Neck
hdl
1887/4010625
doi
10.1002/hed.27907